NCT05934838Active, not recruitingPhase 1
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pills before and after receiving their CAR T cell therapy, for up to 12 months after CAR T cell administration. Patients will be followed for up to 5 years.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 28 Jun 2023
- Start date
- 4 Oct 2023
- Primary completion date
- 30 May 2026
- Lead sponsor
- Weill Medical College of Cornell University
- NCT number
- NCT05934838
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 15
- From 4 Oct 2023 to the primary completion date, 30 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unable to take oral medication
Other illness
- Active viral infection with HIV or hepatitis type B or C
- Active, uncontrolled systemic fungal, bacterial or viral infection
- Active treatment for another cancer
- Certain significant past medical history, such recent stroke, pulmonary embolism, myocardial infarction, congestive heart failure, uncontrolled hypertension, or certain arrhythmias
Other
- Pregnant or breastfeeding
Who the study is looking for
- Confirmed diagnosis of DLBCL, FL, or MCL
- Eligible to receive standard of care CAR T cells
- Have received at least 1 prior therapies
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Weill Cornell Medicine/NewYork-Presbyterian Hospital Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.